OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Ann Oncol 2019; (doi:10.1093/annonc/mdy522) In the original article, the wrong supplementary material was accidentally uploaded. This has now been corrected. The Publisher apologizes for the error. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancerAnnals of OncologyVol. 30Issue 2PreviewPatients with HPV+ oropharyngeal squamous cell carcinoma were assigned to dose and volume de-escalated radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy in an effort to limit treatment-related toxicity while preserving efficacy. Full-Text PDF Open Archive